Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Ajinomoto Health & Nutrition North America, Inc. (AHN), a leader in amino acid science and cell culture ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced an expanded Series A and new appointments to its executive leadership team, board of ...
Delve into the Open Building approach, promoting long-term stewardship and adaptability in architecture amid today's housing ...
Through the collaboration, Applied StemCell is providing Syntax Bio with iPSC lines, including its GMP-compatible hypoimmune iPSC platform, which combines immune-evasion genome engineering with ...
Syntax Bio expands Series A to $14.4M to boost CRISPR Cellgorithm platform and type 1 diabetes beta-cell therapy amid tough biotech funding—read more.
The hottest new programming language is English. Andrej Karpathy, OpenAI co-founder and former Tesla AI director, said this ...
The path from block-based programming to vibe coding represents a shift from mastering the mechanics of implementation to ...
"When a compliance function is well aligned with the organization's needs and business objectives, there is generally little ...
Praxis Precision Medicines, Inc. Strong Buy: key PDUFA dates, NDA catalysts in rare CNS, BTD elsunersen data, and strong cash ...
Peripheral neuropathy is more than numbness: this article explains its symptom, circulation, and nerve layers and a clinic’s ...
Jim Flyzik, who died on June 4 at age 72, played a critical role in this transformation as a long-time IT executive at the ...
In preclinical work and a small clinical trial, adding probenecid to the only approved PKD drug, tolvaptan, cut patients’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results